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Abstract Introduction: Hepatitis 
B vaccine can prevent perinatal 
transmission if administered 
within 24 hours of birth. Nigerian 
infants are known to present late 
for their first immunizations and 
may acquire the virus either verti-
cally or horizontally before re-
ceipt of the first dose of hepatitis 
B immunization. This study 
evaluated serological markers for 
hepatitis B virus infection in Ni-
gerian infants prior to receipt of 
the first dose of hepatitis B immu-
nization. 
Method: Blood samples obtained 
prior to the receipt of hepatitis B 
vaccine from infants presenting 
for their first immunization were 
analysed for HBsAg, antiHBc and 
antiHBe.. 
Results: The mean age at presen-
tation of the 153 infants studied 
was 14.3±15.6 days while only 
two infants presented on the first 
day of life. The prevalences of 
HBsAg and antiHBc were 16.3% 
and 15.7% respectively. Of those 
positive for either HBsAg or an-
tiHBc  20(47.6%) were positive 
for antiHBe. The presence of 
HBsAg was not significantly asso-
ciated with sex, age, circumcision, 
ear piercing and blood transfusion. 
Conclusion: Majority of the in-
fants did not receive hepatitis B 
vaccine within 24 hours of birth. 
Institutional delivery should be 
encouraged while emphasizing to 
mothers and health care workers 
that hepatitis B vaccination must 
commence within 24 hours of 
birth.  
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Universal infant immunization has been recommended 
since 1992 by the World Health Organization as the 
strategy to prevent hepatitis B infection.1 There are dif-
ferent schedules for infant immunization.2 Schedules 
which include a birth dose are able to prevent perinatal 
transmission.2 In such schedules, Hepatitis B vaccine 
should be administered within 24 hours of birth. When 
Hepatitis B vaccine is given alone at birth, it is more 
than 90% effective in preventing vertical transmission2 
whereas the concomitant administration of hepatitis B 
immune globulin improves the protection of infants.3 
In Africa horizontal transmission through close contact 
within households, medical procedures and traditional 
scarifications is thought to be the main route of trans-
mission.4 Even though the major route of transmission is 
horizontal some children still acquire the infection verti-
cally. In Senegal 7% of newborns were shown to be 
HBsAg seropositive at birth.5 Also in Ghana 1.3% of 
newborns were found to be HBsAg positive.6  In a study 
from the study locale 0.96% of newborns were found to 
be HBsAg seropositive.7 Thus commencing immuniza-
tion at birth is the better option preventing both vertical 
and horizontal transmission. Most countries in the Afri-
can sub-region utilize the Expanded Programme on Im-
munization (EPI) schedule which recommends Hepatitis 
B vaccine to be given at birth. 
 
 Endemicity of hepatitis B is defined based on the pro-
portion of the population who are HBsAg seropositive. 
Areas with ≥ 8% of the population being HBsAg posi-
tive are highly endemic while areas with 2-7% HBsAg 
seropisitivity are of intermediate endemicity; <2% 
HBsAg seropositivity represents low endemicity.2The 
prevalence of hepatitis B surface antigen ranges between 
9.1 and 12.6% in the general Nigerian population,8-10 
indicating that Nigeria is highly endemic for hepatitis B 
virus infection. Nigeria operates the EPI schedule of 
commencing hepatitis B vaccination at birth;11 two fur-
ther doses at 6 weeks and 14 weeks completes the 
schedule. The efficacy of hepatitis B vaccine in prevent-
ing vertical transmission depends on its being given in a 
timely fashion, that is the birth dose being administered 
within 24 hours of birth.2 Several reports from Nigeria 
have shown that many infants commence immunization 
late.12,13 In one community based study the mean age at 
commencement of immunization was 32.11 ±49.17 days 
while up to 31.7% of the studied children commenced 
immunization after 28days of life.12 Also only 35% of 
deliveries in Nigeria take place in  health facilities,14 
therefore the birth dose of hepatitis B may not be giv n 
within 24 to 48 hours except the baby is immediately 
taken to a health facility. Previous studies have however 
noted that even babies born within health facilities do 
not commence immunization within 24 hours of birth.`12 
These delays in commencement of immunization may 
place the infant at risk of acquiring the hepatitis B infec-
tion before the commencement of immunization. A pre-
vious study had shown that immunization of those al-
ready infected does not reduce the risk of chronic infec-
tion.15 Thus administration of hepatitis B vaccine to a 
child who is already infected may not prevent chronic 
HBsAg carriage and would constitute a waste of re-
sources.  
 
The success of an immunization programme in prevent-
ing perinatal transmission may be assessed by the pro-
portion of infants who receive the first dose of hepatitis 
B vaccine within 48 hours of birth.2 The World Health 
Organization suggests that timely delivery of the birth 
dose should be a performance indicator for all immuni-
zation programmes.3 Delays in commencement of hepa-
titis B immunization may compromise the effectiveness 
of the hepatitis B control programme as many cases of 
delayed commencement of immunization who become 
infected will be erroneously classified as vaccine fail-
ures. The administration of hepatitis B vaccine to infants 
who are already infected is also a waste of resources. 
This study therefore set out to ascertain prospectiv ly 
the age at commencement of hepatitis B immunization 
and to determine the HBsAg status prior to the com-






The study was carried out at the Immunization clini of 
the Institute of Child Health, University of Benin, Benin 
City between December 2010 and June 2011. The Insti-
tute of Child Health Immunization clinic offers services 
to the inhabitants of Benin City, the capital of Edo state, 
Nigeria. The services offered include immunizations, 
growth monitoring, nutrition education and general 
health education. About 1000 babies receive their immu-
nizations in this facility yearly. 
The sample size was determined using the formula:16 
                     n = z2pq 
                             d2 
where  
n =  the desired sample size 
z = the standard normal deviate set at 1.96 which corre-
sponds to 95% confidence interval  
p = the proportion in the target population estimated o 
be positive for the hepatitis B surface antigen (estimated 
to be 10.8% using the prevalence found in an earlier 
study in Benin City)17 
q = 1.0 – p 
d = degree of accuracy desired which is 0.05 
This gave a sample size of 148.03 which was approxi-
mated to 150. Consecutive infants who were brought for 
their first immunization were recruited.  Any child 
whose birth weight was less than 2kg was excluded 
since babies who have not attained a weight of 2kg are 
not offered hepatitis B vaccine. 
Information on bio data such as date of birth, sex,mater-
nal and paternal educational level and occupation were 
obtained using a proforma. Information on place of 
birth, receipt of antenatal care, birth weight, any illness 
since birth and blood transfusion was also sought.  
              
Two mls of blood was obtained through venepuncture 
under sterile conditions prior to the administration f 
any vaccine. The blood was spun and serum separated 
and then stored at -20°C until the time of testing.  
HbsAg and anti Hbc were assayed for in the serum using 
DRG Hepatitis B surface antigen Enzyme linked immu-
nosorbent assay kit (EIA-3892) and DRG Anti-Heoatitis 
B core antigen Enzyme linked immunosorbent assay kit 
(EIA-3894) reapectively both  manufactured by DRG 
international inc. USA.  
Any sample that was positive for either HBsAg or an-
tiHBc was tested for the presence of antiHBe using 
DRG Anti-Hepaitis B e Antigen Enzyme linked immu-
nosorbent kit by DRG international inc- USA.. The tests 
were carried out by a Laboratory scientist according to 




Ethical clearance for the study was obtained from the 
UBTH ethical review committee. Verbal consent was 
obtained from parents of subjects after the objectiv s 





Sociodemographic characteristics of the study popula-
tion 
 
There were 153 infants, 72(47.1%) girls and 81(52.9%) 
boys. The median age of the babies was 14.3±15.6 days 
with a range of 1 to 90 days. Of the 153 babies, 66
(43.1%) presented in the first week of life.(Table1). 
Only one child presented within a day of life while 6
(3.9%) presented within 2 days of life and 13(8.5%) 
presented within the first 3 days of life.  Sixteen (10.5%) 
babies presented after the 4th week of life. 
The age range of the mothers was 18-42years with a 
mean of 29.6±5.6years.  The mean parity of the mothers 
was 2.7±1.7 with a range of 1 to 10. Most 141 (92.2%) 
of the mothers had antenatal care but only 124(81.1%) 
were delivered in orthodox health care settings. Of those 
who were delivered in orthodox health care settings, 51
(41.1%) were in government owned facilities while 73
(58.9%) were in private facilities. Of the 29 who were 
delivered outside orthodox health care setting 14 were 
delivered at home, 8 in churches, 4 with traditional birth 
attendants and one each with a midwife and nurse. Of 
the 153 mothers only 9(5.9%) were screened for hepati-
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tis B antenatally while 91(59.5%) were not screened. 
The remaining 53(34.6%) did not know if they had been 
screened as they had been asked to do tests whose 
names nor results were unknown to them. All 9 mothers 
who were screened tested negative and did not require 
any intervention. The mean number of persons in the 
household of the infants was 5.2±1.8 with a range of  
2-11  
  










Table 3:  Serological profiles of studied children 
Age at presentation for immunization and presence of 
serological markers for hepatitis B 
 
Serological markers (HBsAg and antiHBc) were present 
in 42 (29.4%) babies. HBsAg was present in 25(16.3%) 
babies while antiHBc was present in 24(15.7%) babies. 
Of the 42 babies with HBsAg and antiHBc 20(47.6%) 
had antiHBe. There were 7(4.6%) babies who were posi-
tive for both HBsAg and antiHBc while 11(7.2%) were 
positive for HBsAg and antiHBe.(Table 2) All three  
Characteristic                                      n                 % 
Gender 
     Male                                                  81              52.9 
     Female                                              72              47.1 
Age at presentation(in days) 
      1-7                                                     66              48.1 
      8-14                                                     42              27.5 
     15-21                                                       23              15.0 
     22-28                                                         6                3.9 
      ≥29                                                     19              10.5 
Place of Delivery 
Within Health facility                             124             81.1 
Outside Health facility                             29            18.9 
Number of persons in household 
         ≤4                                                     60            39.7 
          ≥                                                       91           60.3 
markers were present in 5(3.2%) babies.  Some 14
(9.2%) babies were positive for antiHBc and antiHBe. 
HBsAg alone was present in 18(11.8%) babies while 
antiHBc alone was present in 17(11.4%). 
 
Of the 66 babies who presented in the first week of life 
11(16.7%) were positive for HBsAg (Table 3) whereas 7
(16.7%) of 42, 4(17.4%) of 23, none of 6 and3(18.8%) 
of 16 babies presenting in the second, third, fourth and 
beyond the fourth weeks of life respectively were posi-
tive for HBsAg. Age was not significantly associated  
with being positive for HBsAg. AntiHBc was positive in 
10(15.2%) of 66,7(16.7%) of 42,4(17.4%) of 23, none f 
6 and 3(18.8%) of 16 babies presenting in  the first, sec-
ond, third, fourth and beyond the fourth weeks of life
respectively.  
 
Determinants of presence of serological markers 
 
Of the 81 males 11(13.6%) were HBsAg positive and 
this was not significantly different from 14(19.4%) of 72 
females p=0.38. The number of persons in the household 
of the infant, ear piercing and circumcision were not
significantly associated with the presence of HBsAg in 










using sterile pin ear rings. Of the 25 infants who had 
been circumcised, 12(48%) were done in health facili-
ties. Of the 13(52%) that were done at home 5(38.5%) 
were carried out by health care personnel. The place of 
delivery was also not associated with the presence of 
serological markers. Jaundice was not significantly asso-
ciated with the presence of HBsAg. (Table 4). 
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Table 2: Relationship between age at presentation for immunization and presence of serological markers of hepatitis 
B infection 
Age at presentation                                          Serological Markers 
  In days                                    HBsAga                                AntiHBcb                              AntiHBec 
                                         Positive     Negative              Positive        Negative        Positive     Negative 
                                          n       %    n       %               n      %          n      %             n      %       n       % 
     1-7                               11   16.7   55  83.8             10   15.2       56    84.8           9    16.1    57    86.4 
     8-14                              7   16.6   35  83.3                7   16.6        35   83.4           6    14.3    36    85.7 
    15-21                             4   17.4   19 82.6                4   17.4        19   82.6         4    17.4    19    82.6 
    22-28                             0     0.0     6 100.0               0     0.0          6  100.0          0      0.0      6   100.0 
     ≥29                               3   18.8   13   81,2                3    18.8       13    81.2       4    25.0    12   75.0 
a χ2 0.029 p=0.99      bχ2 0.045 p=0.98       cχ20.39 p=0.83 
The age groups 15-21,22-28 and ≥29 were merged for the Chi square analysis 
Serological Profile                            n                % 
HBsAg only                                     18              11.8 
AntiHBc only                                  17                11.1 
HBsAg +AntiHBc                            7                   4.6 
HBsAg +AntiHBe                           11              7.2 
AntiHBc+AntiHBe                          14              9.2 
All three markers                               5                   3.3 
Any marker                                       42               29.4 






Almost a third of the studied infants had one or more 
hepatitis B serological markers. This is a reflection of 
maternal exposure to the virus indicating the high level 
of hepatitis B endemicity in the study locale. The pr s-
ence of HBsAg in 16.3% of the newborns is much 
higher than the 0.96% documented in a study on paired 
maternal infant samples in the study locale published in 
2001.7 In that study maternal HBsAg seroprevalence 
was 2.19%. In a more recent study( carried out in 2010) 
from the study locale a seroprevalence of 12.8% was
found in pregnant women indicating a higher prevalence 
than the earlier study.18A higher prevalence as docu-
mented by the latter study is likely to be associated with 
higher transmission as observed in the current study 
which was carried out at about the same period. 
 
Compared to the 7%   documented in Senegalese infants 
at birth the finding in this study is also higher.5 The age 
range in this study is wider than for the birth cohort in 
both the Senegalese study and the study on paired sam-
ples from the study locale. This may explain the higher 
HBsAg seroprevalence observed in this study. However, 
50% of the Senegalese infants who were HBsAg posi-
tive at birth had become negative at age 6-7months. In 
that study it is not stated if Hepatitis B vaccine was 
given to the babies postnatally. In other studies in which 
hepatitis B vaccine was given most of the babies were 
negative subsequently.19,20 There were however, some 
positive cases which were considered vaccine fail-
ures.19,20 In  these studies hepatitis B vaccine was admin-
istered within 24 hours of birth and in some Hepatitis B 
immunoglobulin was also given  within 12-24 hours of 
birth.19-21 In this study none of the HBsAg positive in-
fants had received the hepatitis B vaccine within 24 
hours of delivery. With less than five percent of the 
studied infants receiving the hepatitis B vaccine within 
48 hours of birth it is possible that many of these infants 
would remain seropositive. Follow up of these sero-
positve infants is imperative to determine those who 
become chronic carriers so that appropriate follow up 
and care can be given to them.  
 
One of the strategies for the prevention of perinatal 
transmission of hepatitis B is screening of pregnant 
women for hepatitis B surface antigen and then offering 
the hepatitis B vaccine and immune globulin to infants 
of positive mothers within 24 hours of delivery.2 In this 
study almost 60% of the mothers were not screened for 
hepatitis B while only 5.9% were screened. With such 
low screening rates this strategy is unlikely to be eff c-
tive in preventing perinatal transmission. Educating 
health care workers on the importance of screening for 
HBsAg in pregnant women is a strategy that may im-
prove the uptake of this intervention especially in popu-
lations where coverage of antenatal care is high as in the 
mothers in this study. 
AntiHBc has been known to cross the placenta,22 nd it 
has been shown that up to 80% of Nigerian adults have 
one or more markers of hepatitis B exposure by the age 
of 40 years.8 Thus the presence of antiHBc in 15.7% of 
the studied infants may be due to transfer of  matern l 
antibodies. In one study it was found that all infants 
born to mothers who were antiHBc positive were also 
positive for this marker.22 The marker was however no 
longer positive by the age of two years in infants who 
were free of the infection. But those who became 
HBsAg positive were persistently positive for the an-
tiHBc from birth.22 The test in this study did not distin-
guish between IgM and IgG anti HBc. IgM antiHBc will 
suggest infection of the baby. Some studies have how-
ever suggested that in hepatitis B infection in infancy 
IgM anti HBc is not elaborated.5  
 
In another study on the significance of antiHBc it was 
noted that majority of infants who were IgG antiHBc 
positive became negative after six months.23 In that 
same study however significantly more infants (24.6%) 
who were IgG antiHBc positive became HBsAg positive 
compared to 10.9% of those who were antiHBc nega-
tive.23 Thus the presence of antiHBc may be a risk factor 
in the infants in the current study.   
The presence of antiHBe may also be an indication of 
transfer of maternal antibodies as it has been shown t  
also cross the placenta.22 In a study which evaluated 
children serially from birth till 24 months antiHBe was 
found in all infants born to mothers who were HBeAg 
negative but antiHBc positive.22 AntiHBe was not found 
in any of the infants born to HBeAg positive mothers. 
The finding in this study may thus suggest a high leve  
of antiHBe and low level of HBeAg in the mothers. It 
has been suggested that HBeAg which indicates high 
infectivity is not as common in Africa compared to 
South East Asia; hence the relatively smaller role f 
perinatal transmission in Africa compared to South East 
Asia.4 
 
We note the increasing proportion of infants with  
Parameter                               HBsAg                        Fisher’s Exact 
test 
                                               Positive         Negative                 pvalue 
                                                 N          %          n         % 
Gender 
     Male                                    11      13.6      20       86.4 
     Female                                 14      19.4    58        80.6        0.38 
Number of persons in HH 
       ≤4                                      10      16.7      50       83.3 
       ≥5                                      15      16.5      76       83.5         1.00 
Ear Piercing 
       Yes                                     4       20.0     16        80.0 
        No                                     21      15.8     112     84.2         0.75 
Circumcision 
       Yes                                     5       18.5      22       81.5 
       No                                      20     15.9      106     84.1         0.78 
Place of Delivery 
Within health facility                21     17.1     102      82.9 
Outside health facility               4       13.8     25        86.2        0.79 
 Jaundice 
         Yes                                  7        18.0      32       82.0 
         No                                   18     15.9      95        84.1        0.83 
Parity 
     1                                           9      20.5     35       79.5 
   ≥2                                          16      15.1      90       84.9         0.47 
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serological markers with age although this was not sta-
tistically significant it may suggest increasing exposure 
to the virus postnatally emphasizing the need for infants 
to receive the hepatitis B vaccine on time (that is at 
birth). 
Sex was not significantly associated with being positive 
for serological markers. Although intrafamilial spread of 
hepatitis B has been documented,24 in this study there 
was no significant association between being seroposi-
tive and the number of persons in the infants’ household. 
This may suggest that horizontal exposure may be less 
significant in early infancy 
Invasive procedures have the potential for transmision 
of hepatitis B if unsterile instruments are used. In this 
study circumcision and ear piercing were not associated 
with being seropositive for markers of hepatitis B infec-
tion. This is in keeping with previous findings.25-27 This 
is probably due to the use of sterile earrings for ea
piercing both for ear piercing that was done in hospitals 
and those that were done at home. Almost half (48%) of 
the circumcisions were done in health care facility. For 
those done at home 38.5%% were done by health care 
workers who are also unlikely to use contaminated in-
struments.  
 
The place of delivery was also not associated with sero-
positivity. A history of neonatal jaundice or the presence 
of jaundice on examination were not significantly asso-
ciated with seropositivity. This is also in keeping with 
previous studies.5 
 
The presence of serological markers in up to a third of 
infants studied may be a reflection of maternal exposure 
to hepatitis B infection which suggests a high leve of 
prior maternal exposure to the virus. This is in keeping 
with the level of endemicity of hepatitis B in Nigeria. 
However the presence of HBsAg may be indicative of 
infection. Early immunization within 24 hours of birth is 
recommended as this can prevent the development of 
chronic carrier state. Since all the children who were 
HBsAg positive did not receive the vaccine within 24
hours of birth follow up with testing will be mandatory 
to determine those who have become infected.  
 
Using the proportion of infants receiving the birth dose 
of hepatitis B within twenty four hours as performance 
indicator shows that the immunization programme in the 
study locale is performing sub optimally with less than 
five percent of the studied infants receiving hepatitis B 
in the first 48 hours. This immunization programme ay 
thus not be effective in preventing perinatal transmis ion 
of hepatitis B.  
 
The need for timely administration of the hepatitis B 
vaccine within 24 hours of birth should be emphasized 
to both parents and health care workers so that babies 
born within health care facilities will be offered hepatitis 
B vaccine within 24 hours of birth. In a previous study it 
was found that among children who completed the im-
munization schedule  there was no significant difference 
in the age at commencement of immunization between 
babies born in health facilities and those born outside 
health facilities.12 The authors suggested that perhaps 
women irrespective of where they were delivered can be 
motivated to bring their children for immunization.12 
This is relevant since administering a birth dose may 
pose challenges for babies born outside of health fcili-
ties. Thus emphasizing to mothers that immunization 
should be commenced within 24 hours may be all that is 
required.  
 
Other strategies such as the use of single dose vials dur-
ing home visits by health care workers may be explored 
while making every attempt to increase institutional 
deliveries. Single dose vials (such as pre-filled single-
use injection devices like UNIJECTTM) used outside of 
the cold chain have been reported to simplify logistics, 
minimize vaccine wastage and facilitate the speed and 
efficiency of immunization during home visits.2 A fur-
ther challenge to achieving timely administration of the 
birth dose of hepatitis B vaccine is that some healt  f -
cilities do not vaccinate every day. Single dose vials 
may also find utility in such settings as it will obviate 
the need to open multi dose vials for the single baby 
who presents for the birth dose of the hepatitis B vac-
cine. Also identifying women who are carriers through 
prenatal screening and then offering the vaccine and 
HBIG within 24hours of delivery may be a useful strat-
egy. This may be a worthwhile strategy for the popula-
tion of women studied but may not be effective at n-







This study has shown that a high proportion of infants 
have serological markers for Hepatitis B infection prior 
to commencing immunization. Majority of these infants 
did not present within the first 48 hours of life for im-
munization a practice that may compromise the effec-
tiveness of the hepatitis B prevention programme. Fol-
low up of these infants is required to determine those 
who are persistently infected and also to determine the 
effectiveness of hepatitis B vaccine administered at if-
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